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Abstract
Purpose As demand for genetic testing grows and a wide range of health care professionals (HCPs) are potentially involved in 
discussions about testing and delivering results, we developed an educational package to help HCPs with these conversations.
Methods To inform the content of training materials, we conducted interviews with 11 women four of whom had BRCA1 
and seven with BRCA2 mutations. Five women had or were currently receiving breast cancer treatment. Ages ranged from 
38 to 77 years. Interviews were audio-recorded, transcribed verbatim and analysed using the Framework approach to the-
matic analysis.
Results We identified 18 themes and 12 subthemes across the interviews, encompassed by six overarching themes: risk, 
decision-making, information and understanding, communication and improvement, accessing the system: process and 
frustration, emotional and social drivers.
Conclusions The findings informed the didactic components of an educational communication workshop and a summary 
document for attendees. Qualitative interviews provide an important way of incorporating the patient perspective into com-
munication training materials for HCPs by highlighting key issues that matter most to the patient.
Keywords Communication · Genetic testing · BRCA  · Breast cancer · Qualitative
Introduction
BRCA1 or 2 mutations may convey lifetime (to age 80) risks 
of breast cancer of up to 72% and 69%, respectively, and 
44% and 17% risks of ovarian cancer [1]. Demand for acces-
sible testing is growing but genetic services are operating 
under rapidly increasing strain and demand may exceed the 
availability of counselling services. As a result, many differ-
ent healthcare professionals (HCPs) are potentially involved 
in discussions about the need for genetic testing, the con-
sequences of a test result and implications for other family 
members [2, 3].
To provide genetic risk assessment, testing, and coun-
selling, HCPs need a sound knowledge base, good 
communication skills and an ability to offer appropriate psy-
chosocial support [4–6]. They must be able to interpret and 
then clearly convey risk information together with the impli-
cations this has for referral and management options [7]. 
This can be particularly challenging as many HCPs struggle 
when explaining numerical data [8]. Checking understand-
ing and tailoring the discussion accordingly is essential [6, 
7, 9, 10] while ensuring adequate detail is provided to meet 
standards for informed consent [11]. Recognition of the 
emotional context is also crucial, but such concerns are not 
consistently explored [12].
Given the difficulties inherent in communication about 
genetic risk, it is unsurprising that HCPs without specific 
genetic training may lack confidence when having such dis-
cussions [13, 14]. Some communications guidance is avail-
able for clinicians [15], but most HCPs would benefit from 
more focussed and specific training in this area. * Valerie Shilling 
 v.m.shilling@sussex.ac.uk
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The TRUSTING educational programme
We developed the TRUSTING (Talking about Risk, Uncer-
tainties of Testing IN Genetics) educational programme 
in close collaboration with experienced doctors, genetic 
counsellors, geneticists and patients, to expand the com-
munication skills of all HCPs now involved in genetic risk 
discussions.
TRUSTING workshops contain a mix of didactic presen-
tations, exercises and facilitated group discussions around 
filmed scenarios created specifically for the programme; 
these show HCPs discussing risk and genetic testing in the 
context of breast cancer germline mutations with different 
members of a fictitious affected family. Topics covered dur-
ing the workshops include research-based evidence about 
ways to present complex information and risk information, 
ethics, communication about family history, what genetic 
testing means for family members, discussing BRCA test 
results and implications with gene mutation carriers and 
those who test negative, together with the impact that health 
literacy and numeracy exerts on decision-making.
We describe here a qualitative interview study with 
women with or without a diagnosis of breast cancer, who 
tested positive for a BRCA1/2 mutation. Our primary objec-
tive was to explore their views and understanding about 
the genetic testing process and experiences when talking 
to HCPs. Results helped highlight key issues around com-
munication, information needs and decision-making which 
were then used to develop some of the training materials for 
the TRUSTING programme.
Materials and methods
Participants
Women with a known BRCA 1/2 gene mutation who were 
over 18 years of age and able to speak and read English were 
eligible for the study. Women in the process of genetic test-
ing without a known result were excluded.
Participants were recruited via BRCA support groups and 
family history clinics. The invitation was circulated by group 
coordinators; those interested contacted SHORE-C research-
ers directly. Potential interviewees were sent the Participant 
Information Sheet in advance of a telephone call from a 
researcher. Signed informed consent was received from all 
participants.
Though largely a sample of convenience, we purposely 
sampled women who already had a breast cancer diagnosis, 
together with others without breast cancer who had tested 
positive for a gene mutation and who may have had risk-
reducing surgery.
Interview topic guide and procedure
We conducted thematically focussed interviews around five 
broad topics identified a priori: discussion of risk and pres-
entation of risk information; information needs and informa-
tion provided; communication style and approach; under-
standing; decision-making. These key areas for discussion 
were identified through literature review, group discussion 
with local peer support groups for women with a positive 
BRCA1/2 diagnosis, and through discussion within the 
research team. Participants were, however, encouraged to 
speak freely, raising topics of importance to them even if 
these were not prespecified in the topic guide.
Interviews were conducted by an experienced qualitative 
researcher (one of the authors, VS or SC), face-to-face or 
by telephone, at a time and place convenient to participants 
depending on their preference and location. Duration was 
participant guided and lasted between twenty-five minutes 
to over an hour. All were audio-recorded and transcribed 
verbatim.
Data analysis
We applied the Framework Approach (Ritchie and Spencer 
[16]) to thematic analysis, which is a systematic and rigor-
ous methodology for applied qualitative research permitting 
the data to be interrogated with a priori areas of interest in 
mind, rather than being an entirely inductive approach [17].
The Framework Approach involves five distinct stages: 
(i) familiarisation with the data (ii) identifying a thematic 
framework—identifying the key concepts and issues both 
a priori and those emerging from the data of individual 
respondents and recurring concepts; (iii) indexing—apply-
ing the framework to the transcripts; (iv) charting—extract-
ing data from its original context, summarising and group-
ing it in chart form according to the thematic reference; (v) 
mapping and interpretation.
Following the five stages of the Framework approach, 
two of the authors (VS and SC) familiarised themselves with 
the data, read the transcripts and established the thematic 
framework. The coding structure was developed incorpo-
rating both deductive elements, based on a priori areas of 
interest identified in the literature and the topic guide, and 
inductive components, as new themes emerged. Sentences, 
phrases or single words were used to generate codes for the 
identification of themes. VS indexed and charted the mate-
rial. SC also indexed and charted 25% of the transcripts, 
allowing for checks to be made for comprehensiveness of 
data extraction, and consistency in the application of the 
index. Differences in interpretation were resolved through 
discussion. In effect, this process ensures that the thematic 
framework is an adequate and appropriate way to group the 
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data and that themes and subthemes are interpreted in the 
same way by different researchers.
Double-coding 25% of the interview data is widely con-
sidered an acceptable proportion to demonstrate consistency, 
or to highlight areas of the framework for refinement. The 
framework categories were continually checked and modi-
fied to ensure themes and subthemes were appropriate to 
index and describe the data fully. A detailed record was kept 
of the analysis process, including definitions of the themes 
and concepts and their application. NVivo12™ software was 
used to manage the data and support analysis.
Results
Participants
We conducted 11 interviews. Four participants were BRCA1 
and seven BRCA2-positive. Five of the 11 had received or 
were receiving treatment for breast cancer. Ages ranged from 
38 to 77 years. All but one was married or partnered and 
employed, part or full-time (Table 1).
Two of the interviews were conducted face-to-face 
and nine by telephone. Over nine hours of interview were 
recorded and transcribed verbatim. In the following quotes, 
[…] indicates short sections of omitted speech.
Findings
We identified 18 primary themes and a further 12 subthemes 
across the interviews. This thematic framework is shown 
in Table 2. There was considerable interaction and overlap 
between themes and subthemes and we classified into six 
overarching themes.
Risk
Risk information was frequently presented as percentages. 
Personality and individual preferences for receiving infor-
mation determined how well this approach was received 
and how participants engaged with risk information. Some 
participants identified themselves as people who like to 
have all the information and who process and engage well 
with percentages in contrast with others who sometimes 
found this information overwhelming and confusing.
My mum […] just wants to be told what’s the best 
thing to do and get on with it and she puts her head 
in the sand. Whereas I need to know my percentage 
of risk.[P6/43yrs/BRCA2/no cancer]
Not all retained the exact percentages they were told but 
most were happy to have retained the gist of the discussion 
rather than the actual numbers presented. Few recalled the 
use of diagrams or pictures, though the potential benefit 
of using these to help with understanding was recognised.
They may well have done but, to be perfectly honest, 
numbers and I don’t mix. It won’t have meant any-
thing other than you’re not at major risk.[P4/77yrs/
BRCA2/cancer]
Similarly, some had a rudimentary grasp of the fact that 
their risk would change over the course of their lifetime 
but were not able to fully articulate exactly how.
I’ve come away with, at the moment, I’m 65% life-
time risk. They have talked to me about the yearly 
risk figures, but I get too confused. And I know it’s 
cumulative, but it doesn’t really mean anything to 
me.[P10/38yrs/BRCA1/no cancer]
Table 1  Participant characteristics
ID BRCA status Time since BRCA diag-
nosis (approx.) (years)
Cancer 
diagnosis
Preventive treatment Age Relationship status Employment status
P1 BRCA2 4.5 No Mastectomy and oophorectomy 54 Married/partner Part-time
P2 BRCA2 20 No Oophorectomy 55 Married/partner Part-time
P3 BRCA1  < 1 Yes Pending 52 Married/partner Full-time
P4 BRCA2 4 Yes None 77 Widowed Retired
P5 BRCA2 6 Yes Mastectomy and oophorectomy 46 Married/partner Full-time
P6 BRCA2 2 No Mastectomy and oophorectomy 43 Married/partner Part-time
P7 BRCA1 12 No Mastectomy and oophorectomy 53 Married/partner Part-time
P8 BRCA1 5 Yes Mastectomy and oophorectomy 47 Married/partner Full-time
P9 BRCA2 7 No Oophorectomy 44 Married/partner Full-time
P10 BRCA1 1 No Oophorectomy 38 Married/partner Part-time
P11 BRCA2 1 Yes Oophorectomy 46 Married/partner Full-time
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Decision‑making
Decision-making processes were influenced by the experi-
ences of family as well as evaluation of personal risk based 
on information provided by HCPs.
I think because I knew that those two people had actu-
ally got a gene fault. As soon as I knew I had it, it was 
like crikey, I just want, I want shot of anything that 
might put me at the same sort of risk as they had really.
[P1/54yrs/BRCA2/no cancer]
Participants did not express uncertainty about the decision 
to have the genetic test but were sometimes unsure about 
whether to then have risk-reducing surgery. For some the 
provision of good screening for breast cancer made the 
decision more difficult to make as it presented a viable 
alternative to surgery, whereas surgery was seen as the only 
feasible option to reduce the risk of ovarian cancer.
With the ovaries it was very clear. This is the best 
option because we can’t screen you, and that was the 
message. But with this, I don’t really know whether it 
will be the right decision or not.[P10/38yrs/BRCA1/
no cancer]
For others, the decision around breast risk-reducing surgery 
was linked to a sense of self and a sense of “being a woman” 
[P3/ 52yrs/BRCA1/cancer]. A number of participants also 
noted that their decision might have been different at other 
stages of life, particularly with reference to having a family.
Five of the participants had received diagnosis and treat-
ment for breast cancer; however, not all were temporally 
linked with their BRCA diagnosis and subsequent decisions. 
Table 2  Thematic framework Theme Subtheme
Accessing the system
Communication breakdown
Disappointment with follow-up
Emotional context
Family communication
Peer support and learning from the experiences of peers
Amount and clarity of information provided
Related to surgery
Related to testing and test results
Relating to psychological support
Information not provided that participant 
would have liked
Communication style and delivery of information
As experienced
As preferred or personality dictates
Continuity of care
Decision-making
Certainty relating to surgery
Certainty relating to testing
Decision-making and stage of life
Role of professionals in decision-making
Uncertainty relating to surgery
Uncertainty relating to testing
General understanding
How meetings with HCPs could be improved to aid understand-
ing and experience
Implications of testing for own and family future
Influence of family members’ experiences
Preparedness to receive test results
Presentation of risk information by HCP
Temporal and contextual relationship of genetic testing to diag-
nosis and cancer treatment
Understanding of and feelings about personal risk
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For those where the processes were contemporaneous, mak-
ing decisions at the same time could be challenging.
So even though I had the information to hand I was 
more focused on the breast cancer because that was the 
reality that we were living with. The other one was if, 
but maybe.[P3/52yrs/BRCA1/cancer]
A significant subtheme in decision-making related to con-
trol and empowerment. Knowledge about BRCA status was 
empowering and enabled participants to take control of their 
future in a meaningful way, and risk can be partially miti-
gated through lifestyle choices enabling a further sense of 
control.
As my godmother said to me, who also had this gene 
mutation […] information is power, and if you know 
you’ve got it you can do something about it [P5/46yrs/
BRCA2/cancer]
Information and understanding
Participants were generally positive about the amount and 
clarity of information they received relating to BRCA testing 
and results, but some were surprised at how much informa-
tion was presented to them in the first discussion and to be 
asked to think about the potential of surgery prior to even 
having their test.
Perhaps you’re better off just having the blood test. 
And then, saying to you, right, if you test positive for 
this gene fault, then we invite you to come up here to 
discuss it all.[P1/54yrs/BRCA2/no cancer]
Most felt prepared to receive their test results, both in terms 
of having enough information and emotional preparedness. 
When considering surgical options, participants valued a 
staged and multi-dimensional approach to information giv-
ing. This might include providing DVDs and booklets, a 
detailed follow-up letter, or having a nurse sit in and/or a 
dedicated nurse appointment. Some participants highlighted 
areas of information that they felt had either not been dis-
cussed at all or inadequately discussed, including the impact 
of surgical menopause and the safety of HRT.
I did feel that the communication with the surgeons 
and the oncologist as well, and always having a nurse 
in the room is so, so, important. And then, having 
the letter to follow-up afterwards to the GP, that I get 
copied on, to explain what it was we talked about.
[P8/47yrs/BRCA1/cancer]
Communication and improvement
Participants were keen that HCPs adopt an individualised 
approach to their communication style, ask patients how 
they prefer to receive information and engage with decision-
making, and tailor the discussion in that way. They particu-
larly valued a personal, relaxed, easy to talk to communica-
tion style that encouraged them to ask questions.
How do you understand information? How do you 
make decisions? […] that could be the first thing and 
then that sets the basis of the relationship.[P6/43yrs/
BRCA2/no cancer]
They don’t just tell you they are going to do x, y and 
z; they involve you. And they listen to what you say.
[P9/44yrs/BRCA2/no cancer]
Participants also made practical suggestions to aid the com-
munication process, such as: making it clear in the invita-
tion letter how much would be covered in the initial genet-
ics appointment, and the benefits of bringing someone to 
that appointment; the benefits of a nurse present at surgical 
consultations to aid discussion and understanding; and the 
possibility of flexible ways to continue the discussion after 
a consultation, such as email follow-up.
I know not everybody has somebody they can go with 
but that to me, sitting there hearing those risks when 
you’re just by yourself […] Then having to sit on the 
train and absorb it all by yourself on the way home.
[P1/54yrs/BRCA2/no cancer]
Accessing the system: process and frustration
Some participants discussed a struggle to gain access to 
testing and/or appointments. Once in the system there were 
occasions where participants felt they had to push for their 
own follow-up appointments, which can raise anxiety. At 
least two had appointments cancelled at the last moment or 
forgotten completely, which was frustrating and upsetting.
I felt like I’ve been frustrated because by the time that I 
went to the genetic counsellor, I’d been trying for three 
years to get it.[P6/43yrs/BRCA2/no cancer]
A number expressed disappointment with follow-up, 
particularly after gynaecological surgery. Some conveyed a 
feeling of abandonment, with no follow-up and not enough 
information about effects of surgical menopause and the 
acceptability of HRT. This was compounded by the percep-
tion of insufficient communication between hospital teams 
and GPs, leaving GPs unsure if they can prescribe HRT.
And now I’ve had my oophorectomy, there’s been no 
sort of follow-up. Which I suppose there’s no need for 
it, but I think it would be nice if you could have […] 
OK, you’ve had this now, you’ve reduced your risk to 
this, and just a bit more discussion about the next step.
[P10/38yrs/BRCA1/no cancer]
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Continuity of care and continuity of information provided 
by the different teams in general was sometimes described 
as disjointed.
The genetics team believe that the gynaecology team 
and the breast team speak with each other. And that 
it’s actually like a multi-disciplinary team approach 
and it’s not. And that’s a real shame actually because 
the two in these genetic areas go hand in hand and yet 
they don’t.[P3/52yrs/BRCA1/cancer]
Emotional and social drivers
The tentative balance between the weight given to informa-
tion and discussion provided by HCPS and the influence 
of family experience and emotional context was evident 
throughout the interviews.
All BRCA people I think are making decisions in 
the context of previous experience. We have trauma 
through multiple diagnoses or deaths or whatever in 
our families, of other people, which has affected us and 
we are making our decisions based on that. It’s not just 
the scientific risk of what our particular gene means 
to us scientifically and from a biological perspective. 
It’s what you’ve experienced psychologically also is 
influencing your decision-making.[P6/ 43yrs/BRCA2/
no cancer]
Several issues were raised around family dynamics and 
communication. While a number of participants saw the 
benefits of being able to share information and discuss with 
family members, such an emotive topic can cause friction 
when one party does not react or respond to the news in the 
way that the other expects.
You might be interested to talk to my brother […] he’s 
been avoiding getting tested for about a year now, and 
I don’t really understand what he’s playing at because 
he’s got two daughters.[P11/46yrs/BRCA2/cancer]
Not all families are in contact and many are estranged, 
which can provoke additional feelings of pressure and con-
flict about how to manage information-sharing. Participants 
did not suggest that HCPs could or should do anything to 
facilitate family dynamics, other than perhaps recognise 
and acknowledge that a standard approach will not fit all 
families.
So, there was this pressure, I felt, that what if she’s 
got this and she doesn’t know and I do, and anything 
happens to her and I haven’t told her then I’m going to 
be responsible.[P3/52yrs/BRCA1/cancer]
Many participants referenced the importance of 
peers for emotional support and to ‘fill in gaps’ in the 
information provided by HCPs and aid decision-making. 
While more formal, organised support meetings were val-
ued for providing reliable information, participants also 
discussed the use of Facebook groups for advice.
As far as the geneticist, the genetic counsellor, the 
Family History Clinic, they’re talking to you on a 
professional level, which is fine. That gives you the 
knowledge and the data and the facts, but then you 
need, sometimes you need a friend in the same boat.
[P2/55yrs/BRCA2/no cancer]
Discussion
We examined the views, experiences and understanding 
about the genetic testing process and discussions with 
HCPs of women who were BRCA-positive. We identified 
6 overarching concepts: risk, decision-making, informa-
tion and understanding, communication and improvement, 
accessing the system: process and frustration, and emo-
tional and social drivers.
Participants valued an individualised approach to com-
munication style which took account of the way they 
preferred to receive information. This was pertinent par-
ticularly when information about risk was presented as 
percentages, with which not all participants could engage.
For the most part participants were positive about 
the amount and clarity of information they were given, 
although the first discussion was sometimes overwhelm-
ing, especially for those also managing diagnosis and 
treatment for breast cancer. For others, the impact of 
surgical menopause and the safety of HRT were emotive 
topics which were felt to be inadequately discussed. The 
need to strike a balance between information content and 
support for individuals’ processing and comprehension of 
that information is reported repeatedly in the literature 
[4–7, 9, 18–20].
Participants used the experiences of, and communication 
with, family members to evaluate their risk and inform deci-
sions. Numerous studies have reported a strong and compli-
cated relationship between family history and choices made 
around risk-reducing surgery. For a detailed account, see 
Padamsee et al. [21]. Peer support, both formal and infor-
mal was important emotionally and to ‘fill in gaps’ in the 
information provided by healthcare professionals and aid 
with decision-making, consistent with other studies [22, 23].
Women sometimes described the positive test result in 
terms of ‘empowerment’ and ‘control’, as has been reported 
elsewhere [24, 25]. This may provide a useful framework for 
HCPs in their discussions, as a way of enabling women to 
reframe their uncertainty about risk-management decisions.
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Practical application of findings
The findings from this interview study have been used to 
inform the TRUSTING training workshops. Verbatim quotes 
have been used to illustrate and emphasise key points in 
didactic teaching sessions on risk and uncertainty, and to 
stimulate associated discussion points. A detailed take-home 
document was also prepared for workshop attendees, sum-
marising study findings and including direct quotes, to help 
delegates reflect on their approach to these discussions and 
their communication style in general.
Limitations and implications for future research
The study is retrospective in nature; interviewees already 
had a positive BRCA diagnosis. Time had elapsed since 
they had been through the process of talking about genetic 
testing, although discussion and decision-making around 
risk-reducing surgery was often ongoing. As a result, some 
did not always remember well the exact processes involved 
in their referral for genetic testing. Future studies should 
interview participants in a prospective, preferably longitu-
dinal study.
We are aware of the perspectives that are not represented 
in these interviews, such as male family members, people 
who have received a negative test result or findings of a 
variant of unknown significance or practitioners themselves.
Most of the participants were recruited via BRCA support 
groups and may represent a different viewpoint to others 
who do not join a group [26]. One might postulate that peo-
ple who seek out a support group may have had less positive 
experiences or be struggling more with decisions than others 
who do not seek peer support. Reasons for seeking support 
were not explored with interviewees but would be an inter-
esting comparison in future studies.
We did not set out to identify group differences in the 
information needs and understanding of women who had 
and who had not had a diagnosis of breast cancer. However, 
some women in our study who were managing the process 
of genetic testing at the same time as their cancer diagno-
sis and treatment found the process overwhelming, as has 
been reported elsewhere [27]. Dean et al. [28] suggest that 
women who are BRCA-positive but have not had a cancer 
diagnosis have different information needs than those who 
are currently or have previously been diagnosed and treated 
for cancer. This may be an important area for future research.
As our primary goal was practical in nature, our sample 
size was small and our methodological approach did not aim 
for data saturation; we did not seek to describe all possible 
experiences of the process of genetic testing and decision-
making, rather to highlight recurring, significant themes, 
valuable to raise in training.
Conclusion
Using patient narratives in education has been shown 
to help HCPs better appreciate the patient perspective, 
enhancing patient-centredness and improving empathy. 
Incorporating patients’ voices can bring the teaching alive 
and help HCPs reflect on their approach to these challeng-
ing discussions.
These findings have directly informed training materials 
that will be used and tested in a series of seven workshops 
with HCPs in the UK. Participants will complete pre and 
post course assessments to capture any changes in knowl-
edge, confidence and communication skills and provide 
feedback as to the utility of the training programme.
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